Dr. Lingbo Zhang’s Lab at Cold Spring Harbor Laboratory is seeking a postdoctoral fellow to develop novel therapeutics for hematopoietic malignancies. The Zhang Lab is interested in understanding how self-renewal of hematopoietic stem and progenitor cell is regulated under both normal and malignant conditions and how dysregulation of self-renewal process contributes to pathogenesis of various hematopoietic malignancies. The Lab has recently identified multiple promising drug targets to treat hematopoietic malignancies including myelodysplastic syndrome and acute leukemia.
The Lab is addressing these questions through both CRISPR/Cas functional and chemical genomic approaches to identify novel self-renewal regulators and metabolic vulnerabilities and to ultimately develop chemical probes to target these molecular events as novel therapeutics for hematopoietic malignancies. A clinical trial based on one of these drug targets to treat drug-refractory myelodysplastic syndrome is currently under preparation.
The Lab is now seeking an outstanding candidate to functionally characterize drug targets and identify molecular markers that predict responsiveness to these novel therapeutics. The ultimate goal is to develop novel therapeutics for various forms of devastating hematopoietic malignancy.
Cold Spring Harbor Laboratory is a world-renowned biomedical research institution in New York. It has shaped contemporary biomedical research and is the home of eight Nobel Prize laureates. Cold Spring Harbor Laboratory provides a highly dynamic and interactive research environment and also a unique opportunity of timely exposure to advances in various biomedical research fields and of interaction with a broad range of researchers from all over the world through its renowned Meetings and Courses program.
Candidates from non-traditional and/or underrepresented backgrounds, broadly defined, are strongly encouraged to apply.